Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Cordarone I.V.

Executive Summary

Wyeth will ask FDA to reconsider its decision to deny pediatric exclusivity for the antiarrhythmic Cordarone I.V. FDA concluded that the company had provided "insufficient documentation to meet the provisions of the agency's request." Wyeth conducted a 61-patient study in 27 centers in the U.S. and five other countries. Half the patients were from the U.S. Cordarone I.V (amiodarone) was approved in August 1995 under orphan drug status; six months of pediatric exclusivity would have extended protection to Feb. 3, 2003...
Advertisement

Related Content

Wyeth Cordarone I.V. (correction)
Advertisement
UsernamePublicRestriction

Register

PS040669

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel